These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11958837)

  • 1. 6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats.
    Zeng BY; Dass B; Owen A; Rose S; Cannizzaro C; Tel BC; Jenner P
    Neurosci Lett; 2002 Mar; 322(1):33-6. PubMed ID: 11958837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats.
    Zeng BY; Dass B; Owen A; Rose S; Cannizzaro C; Tel BC; Jenner P
    Neurosci Lett; 1999 Dec; 276(2):71-4. PubMed ID: 10624794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
    Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
    Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
    Datla KP; Blunt SB; Dexter DT
    Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits in the substantia nigra, pars reticulata.
    Katz J; Nielsen KM; Soghomonian JJ
    Neuroscience; 2005; 132(3):833-42. PubMed ID: 15837143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase.
    Kunikowska G; Jenner P
    Brain Res; 2001 Dec; 922(1):51-64. PubMed ID: 11730701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
    Medhurst AD; Zeng BY; Charles KJ; Gray J; Reavill C; Hunter AJ; Shale JA; Jenner P
    Neuroscience; 2001; 105(2):353-64. PubMed ID: 11672603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion.
    Granata R; Wenning GK; Jolkkonen J; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1996; 103(3):249-60. PubMed ID: 8739837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-hydroxydopamine lesion of rat nigrostriatal dopaminergic neurons differentially affects nicotinic acetylcholine receptor subunit mRNA expression.
    Elliott KJ; Jones JM; Sacaan AI; Lloyd GK; Corey-Naeve J
    J Mol Neurosci; 1998 Jun; 10(3):251-60. PubMed ID: 9770646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats.
    Sarre S; Yuan H; Jonkers N; Van Hemelrijck A; Ebinger G; Michotte Y
    J Neurochem; 2004 Jul; 90(1):29-39. PubMed ID: 15198664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury.
    Kholodilov NG; Neystat M; Oo TF; Lo SE; Larsen KE; Sulzer D; Burke RE
    J Neurochem; 1999 Dec; 73(6):2586-99. PubMed ID: 10582622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats.
    Wang JY; Wu JN; Cherng TL; Hoffer BJ; Chen HH; Borlongan CV; Wang Y
    Brain Res; 2001 Jun; 904(1):67-75. PubMed ID: 11516412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
    Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE
    Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
    Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
    Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice.
    Naudin B; Bonnet JJ; Costentin J
    Brain Res; 1995 Dec; 701(1-2):151-7. PubMed ID: 8925278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.